Skip to content

Multicentric prospective randomized trial on the effect of analgesic radiotherapy on painful arthroses dependent on the dose

Multicentric prospective randomized trial on the effect of analgesic radiotherapy on painful arthroses dependent on the dose - ARTHRORAD-trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011870
Enrollment
270
Registered
2017-06-12
Start date
2017-07-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M17.1 M18.1 M19.04

Interventions

Group 1: Radiotherapy of the joint, 6 single fractions of 0.5Gy each twice a week up to a total dose of 3.0Gy, total treatment time three weeks Group 2: Radiotherapy of the joint, 6 single fractions o

Sponsors

Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: - clinical diagnosis of a painful arthrosis of the knee joint or of joints of the hand with a minimum duration of symptoms of >= three months. - radiological proof of the arthrosis -typical clinical symptoms (pain after pressure, limitation of motion, swelling) - typical functional deficitis (limitation of mobility or of painless walking distance, limitation of grabbing function - sufficient general health status - age >= 40 years - written informed consent given

Exclusion criteria

Exclusion criteria: - previous radiotherapy to the joint involved - other cause of pain (trauma, rheumatoid arthritis - patients with arthrosis caused by a former rheumatoid arthritis can be included) - intense venous insufficiency - arterial occlusion disease - lymphedema - pregnancy, breastfeeding - intense psychical disorder - legal care for the patient by other persons

Design outcomes

Primary

MeasureTime frame
Primary outcome: pain relief tested three and twelve months after radiotherapy using the VAS scale

Secondary

MeasureTime frame
Improvement of function (three and twelve months after radiotherapy, KOOS-SF or SF_SACRAH-scores, respectively) Improvement of general quality of life (three and twelve months after radiotherapy, SF-12 scores) Use of analgesic medication (complete duration of the trial, medication protocol)

Countries

Germany

Contacts

Public ContactMarcus Niewald

Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes

marcus.niewald@uks.eu06841 1624673

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026